Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cadle, R. M.
Right arrow Articles by Musher, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cadle, R. M.
Right arrow Articles by Musher, D. M.
American Journal of Health-System Pharmacy, Vol. 64, Issue 22, 2359-2363
Copyright © 2007. American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/04/0602-1242$06.00

Note

Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis

 Richard M. Cadle, Mohammad D. Mansouri, Nancy Logan, Denise R. Kudva and Daniel M. Musher

RICHARD M. CADLE, PHARMD., BCPS, is Pharmacy Residency Program Director and Infectious Disease Clinical Pharmacy Specialist, Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC), Houston, TX, Assistant Professor of Medicine, Section of Infectious Diseases, Baylor College of Medicine (BCM), Houston; and Adjunct Clinical Assistant Professor, University of Texas—Austin and University of Houston Schools of Pharmacy. MOHAMMAD D. MANSOURI, B.S., is Instructor, Department of Physical Medicine and Rehabilitation, MEDVAMC and BCM. NANCY LOGAN, M.A., is Research Associate, Section of Infectious Diseases, MEDVAMC. DENISE R. KUDVA, PHARMD., is Clinical Pharmacy Specialist, Pharmacy Service, M. D. Anderson Hospital, Houston; at the time of this study she was Pharmacy Practice Resident, MEDVAMC. DANIEL M. MUSHER, M.D., is Professor of Medicine, Section of Infectious Diseases, MEDVAMC.

Address correspondence to Dr. Cadle at Pharmacy Service (119), Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, TX 77030 (cadle.richardmark{at}med.va.gov).


Purpose. The role of concurrent use of proton-pump inhibitors (PPIs) in the outcomes of treatment for Clostridium difficile colitis was studied.

Methods. The records of inpatients at a large Veterans Affairs medical center in whom C. difficile colitis was diagnosed between June 2004 and July 2005 were retrospectively reviewed. Data collected included patient characteristics at baseline, antibiotic therapy prescribed before and during therapy for C. difficile colitis, concurrent treatment with a PPI, response to therapy for C. difficile colitis, and recurrence of the disease in the 90 days after symptoms resolved. Outcomes of therapy were classified as cures, treatment failures, or disease recurrences.

Results. A total of 140 patients (138 men and 2 women) were included in the study. Ninety-seven (69%) of patients received a PPI and 43 (31%) did not. Of patients receiving a PPI, 37 (38%) were cured of C. difficile colitis, 20 (21%) did not respond to therapy, and 40 (41%) had disease recurrence. Among the non-PPI patients, 27 (63%) were cured, 9 (21%) did not respond, and 7 (16%) had recurrence. Patients receiving PPIs were 4.17 times as likely to have recurrence as their counterparts who did not.

Conclusion. PPI therapy was associated with an increased risk of recurrent C. difficile colitis.

Index terms: Antiinfective agents; Clostridium infections; Combined therapy; Enterocolitis; Gastrointestinal drugs; Toxicity

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Health-System Pharmacists.